home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Diamond Collection
/
The Diamond Collection (Software Vault)(Digital Impact).ISO
/
cdr16
/
med9505d.zip
/
M9550877.TXT
< prev
next >
Wrap
Text File
|
1995-03-25
|
2KB
|
37 lines
Document 0877
DOCN M9550877
TI Biologic effects and safety of stavudine: overview of phase I and II
clinical trials.
DT 9505
AU Skowron G; Roger Williams Medical Center, Brown University School of;
Medicine, Providence, Rhode Island 02908.
SO J Infect Dis. 1995 Mar;171 Suppl 2:S113-7. Unique Identifier : AIDSLINE
MED/95164986
AB Data on the biologic effects and safety of stavudine in patients with
AIDS and AIDS-related complex represent results of two phase I trials (n
= 84), another phase I study of patients with hematologic intolerance to
zidovudine (n = 23), and a phase II trial (n = 152). The daily doses of
stavudine ranged from 0.1 to 12.0 mg/kg. Increases in CD4 cell count,
declines in serum p24 antigen, and weight gain were all related to the
dose of stavudine. Doses of < or = 2 mg/kg/day (n = 216) were
well-tolerated, with a median duration of therapy of > or = 48 weeks in
the phase I studies and > or = 79 weeks in the phase II study. The
predominant dose-limiting toxicity was peripheral neuropathy, which was
related to both the dose and duration of treatment with stavudine.
Elevations of liver enzymes were seen in some patients but appeared to
be related to underlying disease rather than treatment. There was no
evidence of dose-related hematologic toxicity.
DE Acquired Immunodeficiency Syndrome/DRUG THERAPY AIDS-Related
Complex/DRUG THERAPY Body Weight/DRUG EFFECTS Clinical Trials, Phase I
Clinical Trials, Phase II CD4 Lymphocyte Count/DRUG EFFECTS
Dose-Response Relationship, Drug Human HIV Core Protein p24/DRUG
EFFECTS/IMMUNOLOGY HIV Infections/*DRUG
THERAPY/IMMUNOLOGY/PHYSIOPATHOLOGY Peripheral Nervous System
Diseases/CHEMICALLY INDUCED Stavudine/ADMINISTRATION & DOSAGE/*ADVERSE
EFFECTS/THERAPEUTIC USE Support, Non-U.S. Gov't Support, U.S. Gov't,
P.H.S. JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).